Cat. No.: HY-N0931

Santacruzamate A

(Synonyms: CAY-10683)

22 Cited Publications

Customer Review

Based on 22 publication(s) in Google Scholar

Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research.

For research use only. We do not sell to patients.

Purity: 99.54%
CAS No.: 1477949-42-0
Formula: C₁₅H₂₂N₂O₃
Molecular Weight:278.35

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Santacruzamate A Chemical Structure

CAS No.: 1477949-42-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (22)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HDAC2

119 pM (IC₅₀)

HDAC6

434 nM (IC₅₀)

All HDAC Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	>50 μM Compound: 5a; SCA	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	>50 μM Compound: 5a; SCA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29100734]
HCT-116	IC₅₀	>50 μM Compound: 5a; SCA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29100734]
MCF7	GI₅₀	>50 μM Compound: 1; SCA, synthetic	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
MDA-MB-231	GI₅₀	>50 μM Compound: 1; SCA, synthetic	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
PBMC	GI₅₀	>50 μM Compound: 1; SCA, synthetic	Antiproliferative activity against human PBMC assessed as reduction in cell viability after 70 hrs by Quanti-blue assay Antiproliferative activity against human PBMC assessed as reduction in cell viability after 70 hrs by Quanti-blue assay	[PMID: 27614919]

In Vitro

Santacruzamate A (0.016-50 μM, 28 h) attenuates amyloid-β protein fragment 25–35-induced apoptosis and reverses Aβ25–35-induced unfolded protein response and endoplasmic reticulum stress in PC12 and SH-SY5Y. 2 μM STA shows the strongest protective effects^[2].
Santacruzamate A (0.016-50 μM, 12 h) up-regulates KDEL receptor (KDELR) expression, reinforces ER luminal retention of chaperones, and enhances the binding of PERK to GRP78, inhibiting the amyloid-β protein fragment 25–35-induced mitochondrial fission and apoptosis pathways in PC12^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1477949-42-0
Appearance Solid
Molecular Weight 278.35
Formula C₁₅H₂₂N₂O₃
Color White to off-white
SMILES

O=C(OCC)NCCCC(NCCC1=CC=CC=C1)=O
Synonyms

CAY-10683
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Plants
- other families
- Microorganisms
Panamanian Marine Cyanobacterium
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (22)

All WBRT-PCRCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Cancer Cell

Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. [Abstract]

2024 Oct 14;42(10):1729-1746.e8. PMID: 39303724
Cell Metab

Microbial regulation of hexokinase 2 links mitochondrial metabolism and cell death in colitis. [Abstract]

2021 Dec 7;33(12):2355-2366.e8. PMID: 34847376
Adv Sci (Weinh)

The Probiotic Parabacteroides johnsonii Ameliorates Metabolic Disorders Through Promoting BCAAs to BSCFAs Conversion. [Abstract]

2025 Aug 7:e02624. PMID: 40772426
MedComm (2020)

Stearoyl-CoA Desaturase-1 Drives Tumor Growth by Interacting With Histone Deacetylase-2 and Deacetylating Nucleophosmin-1. [Abstract]

2026 Jun 11;7(6):e70809. PMID: 42292857
Cell Rep Med

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability. [Abstract]

2024 Sep 27:101770. PMID: 39368485
Cancer Lett

PD-L1 delactylation-promoted nuclear translocation accelerates liver cancer growth through elevating SQLE transcription activity. [Abstract]

2025 Oct 10:630:217901. PMID: 40614853

Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901. [Abstract]

Western blot assay of lysates from HepG2 and MHCC97H cells treated with Santacruzamate A (CAY-10683) (20 μM; 48 h).

Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901. [Abstract]

Santacruzamate A (CAY-10683) (20 μM; 24-72 h) impeded proliferation of HepG2 and MHCC97H cells.

Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901. [Abstract]

Santacruzamate A (CAY-10683) (20 μM; 48 h) impeded the total cholesterol concentration of HepG2 and MHCC97H cells.
EMBO J

Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis. [Abstract]

2024 Nov;43(21):4954-4983. PMID: 39294473
Br J Pharmacol

Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19. [Abstract]

2024 Oct;181(19):3663-3684. PMID: 38839561

Santacruzamate A purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 Oct;181(19):3663-3684. [Abstract]

Santacruzamate A (CAY-10683) (0.1 μM; 24 h) significantly up-regulated the mRNA expression of FXR, SHP, and FGF19 in IEC-6 cells.

Santacruzamate A purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 Oct;181(19):3663-3684. [Abstract]

Santacruzamate A (CAY-10683) (2 mg/kg; i.p.; 1 h; once daily for 4 weeks) decreased the contents of total triglyceride (TG) and total cholesterol (TC) in the sera and livers and the activities of AST and ALT in the sera of NAFLD (non-alcohol fatty liver disease) mice.
Metab Eng

Metabolic engineering of commensal bacteria for gut butyrate delivery and dissection of host-microbe interaction. [Abstract]

2023 Nov:80:94-106. PMID: 37717646
Clin Transl Med

A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. [Abstract]

2021 Sep;11(9):e545. PMID: 34586732
Stem Cell Reports

Nuclear Lipin1 recruits HDAC2 to epigenetically repress SREBP1-dependent lipid synthesis and myelination in hypoxic preterm white matter injury. [Abstract]

2026 Apr 14;21(4):102853. PMID: 41825445
Immunology

CD5L attenuates allergic airway inflammation by expanding CD11chigh alveolar macrophages and inhibiting NLRP3 inflammasome activation via HDAC2. [Abstract]

2022 Nov;167(3):384-397. PMID: 35794812
Int J Mol Sci

Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition. [Abstract]

2022 Apr 2;23(7):3980. PMID: 35409339
Int Immunopharmacol

Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. [Abstract]

2025 Mar 29:154:114528. PMID: 40158429
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Brain Res Bull

HDAC2 exacerbates carbon monoxide poisoning-induced brain injury by promoting neuronal ferroptosis through the NEDD4L/ACSL4 axis. [Abstract]

2025 Nov:232:111619. PMID: 41192741
Exp Cell Res

Epigenetic silencing of GPD1 by HDAC2 via H3K9 deacetylation promotes head and neck squamous cell carcinoma progression. [Abstract]

2026 Jun 15;459(2):115018. PMID: 41962619
Pulm Pharmacol Ther

Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF-κB/PAI-1 signalling. [Abstract]

2021 Oct:70:102061. PMID: 34314854
Virology

H1N1 swine influenza viruses upregulate NEU1 expression through histone H3 acetylation regulated by HDAC2. [Abstract]

2024 Nov 15:601:110305. PMID: 39566266
bioRxiv

2026 Jun 5.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. [Abstract]

2025 Apr 26:2025.04.23.650241. PMID: 40568091

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (359.26 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5926 mL

17.9630 mL

35.9260 mL

5 mM

0.7185 mL

3.5926 mL

7.1852 mL

10 mM

0.3593 mL

1.7963 mL

3.5926 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Pavlik CM,et al. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5926 mL	17.9630 mL	35.9260 mL	89.8150 mL
	5 mM	0.7185 mL	3.5926 mL	7.1852 mL	17.9630 mL
	10 mM	0.3593 mL	1.7963 mL	3.5926 mL	8.9815 mL
	15 mM	0.2395 mL	1.1975 mL	2.3951 mL	5.9877 mL
	20 mM	0.1796 mL	0.8981 mL	1.7963 mL	4.4907 mL
	25 mM	0.1437 mL	0.7185 mL	1.4370 mL	3.5926 mL
	30 mM	0.1198 mL	0.5988 mL	1.1975 mL	2.9938 mL
	40 mM	0.0898 mL	0.4491 mL	0.8981 mL	2.2454 mL
	50 mM	0.0719 mL	0.3593 mL	0.7185 mL	1.7963 mL
	60 mM	0.0599 mL	0.2994 mL	0.5988 mL	1.4969 mL
	80 mM	0.0449 mL	0.2245 mL	0.4491 mL	1.1227 mL
	100 mM	0.0359 mL	0.1796 mL	0.3593 mL	0.8981 mL

Keywords

Santacruzamate A

22 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Santacruzamate A

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Osteogenesis Compound Library

Marine-Sourced Natural Product Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Santacruzamate A

All HDAC Isoforms

Biological Activity

Chemical Information

Publications (22)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Santacruzamate A Related Classifications

HY-N0931 Related Classifications